Kazia Therapeutics Ltd ADR

The current price of KZIA is $7.00 — it has decreased by 13.37% since the previous close. Data as of Nov 5, 2026.

KZIA is down 19.63% over the past week, down 25.13% over the past month and down 8.85% over the past year. The price is below its 200-day moving average of $10.56.

Analysts' average 12-month price target for KZIA is $33.67, which implies 381.00% upside from the current price. Individual estimates range from $29.00 to $40.00.

Of the 9 analysts covering Kazia Therapeutics Ltd ADR, 3 rate it a strong buy and 6 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

Kazia Therapeutics Ltd ADR has a market capitalization of $11.34M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, Kazia Therapeutics Ltd ADR posted a loss of $0.3295 per share against an estimate of -$0.6055, beating expectations by 45.58%. Upcoming reports are listed in the earnings calendar.

Kazia Therapeutics Ltd ADR reported revenue of $150.39K in its most recent quarter. Analysts had expected $488.86K.

Kazia Therapeutics Ltd ADR has not paid any dividends over the past year.

Companies most comparable to Kazia Therapeutics Ltd ADR include Biodexa Pharmaceuticals Plc, InMed Pharmaceuticals Inc., Soligenix, Inc., CNS Pharmaceuticals, Inc. and GRI Bio, Inc.

In the latest trading session KZIA moved between $7.00 and $7.99, a range of 14.14% of its current price.

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Kazia Therapeutics Ltd ADR shows a strong sell rating today and a strong sell rating on the weekly timeframe. Technical ratings are indicators, not investment advice.

Over the past 52 weeks KZIA has traded between $4.86 and $17.40. The current price is 59.77% below its 52-week high.